Core Insights - Citius Oncology has launched an innovative AI platform to enhance its commercial strategies and support the upcoming launch of LYMPHIR™, a novel therapy for cutaneous T-cell lymphoma (CTCL) [1][2][5] - The AI platform utilizes machine learning to identify treatment patterns and target prescribers effectively, thereby improving patient care and clinical decision-making [2][4][5] - LYMPHIR is a targeted immune therapy approved by the FDA in August 2024 for relapsed or refractory CTCL, with a market potential exceeding $400 million [6][7][32] Group 1: AI Platform and Commercial Strategy - The proprietary AI platform is designed to refine targeting and enhance the efficiency of the salesforce by providing data-informed engagement with healthcare providers [1][3] - It continuously learns from real-world data and marketing performance analytics, delivering predictive insights for tailored customer journeys [4] - The platform aims to optimize the commercial infrastructure and accelerate healthcare provider education [5] Group 2: Product Overview and Market Potential - LYMPHIR is indicated for adult patients with relapsed or refractory Stage I-III CTCL after at least one prior systemic therapy [10] - The therapy is a recombinant fusion protein that targets IL-2 receptors on tumor cells, leading to cell death and enhanced antitumor activity [6] - Citius Oncology estimates the initial market for LYMPHIR to exceed $400 million, indicating significant growth potential in an underserved market [32]

Financial Overview - Citius Pharmaceuticals raised $12.5 million in gross financings during the fiscal third quarter ended June 30, 2025, with an additional $9 million raised in July 2025 for LYMPHIR pre-launch initiatives [1][3] - The company reported a net loss of $9.2 million, or $0.80 per share, for the quarter, an improvement from a net loss of $10.6 million, or $1.57 per share, in the same quarter of the previous year [7][13] Business Development - Citius is transitioning from a development-stage enterprise to a fully integrated commercial organization, with final preparations for the U.S. launch of LYMPHIR™ planned for the fourth quarter of 2025 [2][3] - The company has completed major launch-enabling activities, including commercial-scale manufacturing and distribution agreements, indicating readiness to deliver LYMPHIR to patients with cutaneous T-cell lymphoma [3][6] Financial Results - Research and development expenses for the quarter were $1.6 million, down from $2.8 million in the same quarter of 2024 [7][15] - General and administrative expenses were $4.4 million, compared to $4.8 million in the prior year [7][15] - Cash and cash equivalents at June 30, 2025, were $6.1 million, an increase from $3.3 million at the end of the previous fiscal year [7][9] Capital Structure - The company completed a $6 million registered direct offering in June 2025, with potential additional proceeds of $9.8 million upon full warrant exercise [3][6] - Citius Oncology, a subsidiary, raised $9 million in gross proceeds from a public offering in July 2025 [1][3] Product Pipeline - Citius Pharma's late-stage pipeline includes LYMPHIR™, Mino-Lok®, and CITI-002 (Halo-Lido), with ongoing engagement with the FDA for next steps on these programs [6][3]

Core Viewpoint - Citius Pharmaceuticals Inc. has successfully closed a registered direct offering, raising approximately $6 million, with potential additional proceeds of up to $9.8 million from short-term warrants [1][3]. Group 1: Offering Details - The offering consisted of 4,920,000 shares of common stock priced at $1.22 per share, along with short-term warrants to purchase an additional 9,840,000 shares [1][3]. - The short-term warrants have an exercise price of $1.00 per share, are immediately exercisable, and will expire 24 months from the initial exercise date [1][3]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to support the commercial launch of LYMPHIR™, including milestone and regulatory payments, as well as general corporate purposes [3]. Group 3: Company Background - Citius Pharmaceuticals is focused on developing first-in-class critical care products, with LYMPHIR approved by the FDA for treating cutaneous T-cell lymphoma [6]. - The company also has a late-stage pipeline that includes Mino-Lok®, an antibiotic lock solution, and CITI-002 (Halo-Lido), a topical formulation for hemorrhoid relief [6].

Core Viewpoint - Citius Pharmaceuticals Inc. has announced a definitive agreement to purchase 1,739,131 shares of its common stock at a price of $1.15 per share, with expected gross proceeds of approximately $2 million to support the commercial launch of LYMPHIR™ and general corporate purposes [1][2]. Group 1 - The offering is being facilitated by H.C. Wainwright & Co. as the exclusive placement agent [2]. - The closing of the offering is anticipated to occur on or about April 2, 2025, pending customary closing conditions [1]. - The securities are being offered under a "shelf" registration statement filed with the SEC, which became effective on March 1, 2024 [3]. Group 2 - Citius Pharmaceuticals is focused on developing first-in-class critical care products, with LYMPHIR approved by the FDA in August 2024 for treating cutaneous T-cell lymphoma [5]. - The company's late-stage pipeline includes Mino-Lok®, an antibiotic lock solution, and CITI-002 (Halo-Lido), a topical formulation for hemorrhoid relief, with both products having completed pivotal trials in 2023 [5]. - Citius Pharma owns 92% of Citius Oncology, Inc., indicating a strong position in the oncology sector [5].